Genmab shares rise 1.21% premarket after FDA grants Breakthrough Therapy Designation to Rina-S for endometrial cancer treatment. AInvest
Multifunctional small-molecule theranostic agents hold significant clinical potential for non-invasive endometriosis (EMS) management. Current EMS treatment faces challenges due to imprecise lesion localization and therapy-associated side effects. Herein, an integrated …
Sirtuin 6 Mediates the Therapeutic Effect of Endometrial Regenerative Cell-derived Exosomes in Alleviation of Acute Transplant Rejection by Weakening c-Myc-dependent Glutaminolysis Frontiers
Endometriosis (EMS) is a persistent, inflammatory condition that relies on estrogen and is distinguished by the proliferation of endometrial tissue outside the confines of the uterus. The impact on the …
Endometriosis (EMS) is a chronic inflammatory disorder with ectopic endometrial tissues arising in extrauterine areas. We investigated the mechanism of adenosine triphosphate (ATP)/P2X4 regulating inflammation and oxidative stress in EMS.
Endometriosis is hypothesized to result from retrograde menstruation where cell debris including endometrial stromal cells (ESCs) travel through the fallopian tubes. This chronic inflammatory disease is characterized by inflammatory and …
Current interventions for endometriosis mainly involve hormone therapies but have limited efficacy and unacceptable side effects due to the lack of selectivity to distinguish between endometriosis and endometrial tissues. Elucidating …
The endometrium is a vital mucosal tissue which undergoes cyclical regeneration, differentiation, and remodeling upon hormonal, cellular, and molecular signaling networks. Dysregulation of these processes can trigger a range of …
Rina-S Earns FDA Breakthrough Therapy Designation in Endometrial Cancer CancerNetwork
Genmab's Rina-S: A Game-Changer in Endometrial Cancer and a Catalyst for Shareholder Value AInvest